Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus

ConclusionDapagliflozin treatment of individuals with type  1 diabetes, particularly non-obese individuals and older men, might result in loss of skeletal muscle mass. However, good glycemic control during treatment might prevent the onset and progression of sarcopenia.

Source: Journal of Diabetes Investigation - July 10, 2023 Category: Endocrinology Authors: Yuta Yoshimura, Yoshitaka Hashimoto, Hiroshi Okada, Maya Takegami, Hanako Nakajima, Tomoki Miyoshi, Takashi Yoshimura, Masahiro Yamazaki, Masahide Hamaguchi, Michiaki Fukui Tags: Clinical Trial Source Type: research